Aetna · BRCA Single Gene · US health-plan appeal rights

BRCA Single Gene denied for failing step therapy by Aetna?

Q: How long do I have to appeal a Aetna BRCA Single Gene denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Aetna's specific coverage criteria for brca single gene are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Aetna Clinical Policy Bulletin (Genetic Testing) + Aetna Clinical Policy Bulletin (BRCA Testing) + Aetna Clinical Policy Bulletin (Genetic Counseling)

The Aetna angle on BRCA Single Gene

## Why Aetna Applied a Step-Therapy Denial to Your BRCA Single-Gene Test

Step-therapy (sometimes called "fail-first") denials are unusual for genetic tests, but they do occur when Aetna's policy requires that a broader or less costly test be attempted before a single-gene assay is approved — or, conversely, when a single-gene test is requested but policy requires starting with a multi-gene panel. The denial language may suggest that a different testing approach should have been tried first. This type of denial is appealable because clinical guidelines from organizations such as NCCN and ACMG specify which testing strategy is appropriate based on a patient's personal and family history, and a clinician-directed choice to pursue single-gene testing over a panel (or vice versa) may be medically justified.

## Your Federal Appeal Rights

Internal appeal: Submit within the timeframe on your Explanation of Benefits. Aetna must respond within 30 days (pre-service) or 60 days (post-service) of a complete submission.
External review (ACA §2719 / ERISA §503): After the final internal denial, you have approximately four months to request independent external review by a neutral, accredited organization.
Step-therapy override statutes: Many states have enacted laws that require insurers to grant step-therapy overrides when the required first step is contraindicated, was already tried, or when the prescribing clinician determines it would cause harm. Check whether your state's step-therapy override law applies to your plan.
Expedited review: Available when delay poses an urgent clinical risk.

## What to Gather

1. Clinical rationale for single-gene testing — your ordering clinician's letter explaining why the single-gene approach (rather than a multi-gene panel, or the alternative the insurer requires) is the medically appropriate choice for this patient. 2. Prior testing history — records of any prior genetic tests performed, including dates, platforms, and results, to establish what has already been attempted. 3. Guideline support — reference the applicable NCCN or ACMG hereditary-cancer guideline, which specifies testing strategy based on clinical presentation. 4. Aetna's Clinical Policy Bulletin — identify the exact step-therapy requirement being applied and any override criteria listed. 5. State step-therapy override request — if your state's law applies, file a formal override request alongside or as part of your appeal, citing the relevant statutory provision.

## Criteria-Mapping Structure

List each step in Aetna's required testing sequence. For every step, document either (a) that it was completed with the date and result, or (b) the specific clinical reason it was skipped or bypassed, supported by your clinician's statement and applicable guideline language. If the required first-step test would be clinically inappropriate, the override letter should explain why in concrete, chart-supported terms.

## Bottom Line

Step-therapy denials for genetic testing are legally and clinically challengeable, particularly when the ordering clinician has a documented rationale for the chosen testing strategy grounded in established guidelines. A systematic, criterion-by-criterion appeal with strong clinician support is the most effective path to reversal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other denial reasons for Aetna BRCA Single Gene

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.